Evidence map›Paper›PMID 41702887›Full record

ArticleCell death discovery2026

Modulating metabolic signatures to mitigate cabozantinib resistance in FLT3-ITD acute myeloid leukemia cell models.

Yu-Hsuan Fu, Kit Man Ng, Chi-Yang Tseng, Ang-Chu Huang, Chin-Hsien Tu, Wen-Chun Chen, Pei-Chi Lang, Hsiung-Fei Chien, Liang-In Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yu-Hsuan FuDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.ORCID http://orcid.org/0000-0002-5917-2961
Kit Man NgDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
Chi-Yang TsengDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
Ang-Chu HuangDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
Chin-Hsien TuDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
Wen-Chun ChenDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
Pei-Chi LangDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
Hsiung-Fei ChienDepartment of Surgery, Taipei Medical University Hospital, Taipei, Taiwan. hfchien@h.tmu.edu.tw.
Liang-In LinDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan. lilin@ntu.edu.tw.ORCID http://orcid.org/0000-0002-3561-1093

Funding

Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan) NSCT 112-2320-B-002-008, NSCT 111-2320-B-002-058 and MOST 108-2320-B-002-050-MY3National Taiwan University Hospital (NTUH) 112-S0224, 111-S0023
6 · The paper itself

Abstract

Drug resistance remains a major challenge in treating acute myeloid leukemia (AML), despite advancements in targeted therapies. We established cabozantinib-resistant FLT3-ITD

Identifiers

PMID41702887
PMCPMC12920922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.